BAILLIE GIFFORD & CO 13D and 13G filings for Denali Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-12 10:55 am Purchase | 2024-12-31 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 2,740,102 7.200% | 2,740,102 (New Position) | Filing |
| 2025-02-12 10:52 am Sale | 2024-12-31 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 12,313,931 8.600% | -1,946,793 (-13.65%) | Filing |
| 2024-01-30 06:59 am Sale | 2023-12-29 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 14,260,724 10.320% | -858,750 (-5.68%) | Filing |
| 2023-01-20 10:05 am Purchase | 2022-12-30 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 15,119,474 11.130% | 63,093 (+0.42%) | Filing |
| 2022-01-18 11:50 am Purchase | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 15,056,381 12.330% | 2,866,125 (+23.51%) | Filing |
| 2021-01-12 09:24 am Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | BAILLIE GIFFORD & CO | 12,190,256 10.170% | 4,600,009 (+60.60%) | Filing |